23andMe (NASDAQ:ME) Receives “Sell (E+)” Rating from Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 23andMe (NASDAQ:ME) in a report issued on Saturday morning,Weiss Ratings reports.

23andMe Stock Performance

Shares of NASDAQ ME opened at $2.86 on Friday. The stock has a 50 day moving average price of $3.46 and a 200 day moving average price of $5.18. 23andMe has a 52 week low of $2.65 and a 52 week high of $16.52. The stock has a market capitalization of $74.70 million, a PE ratio of -0.19 and a beta of 1.14.

23andMe (NASDAQ:ME) last issued its quarterly earnings results on Tuesday, January 28th. The company reported ($1.02) EPS for the quarter. 23andMe had a negative net margin of 183.39% and a negative return on equity of 145.99%.

Hedge Funds Weigh In On 23andMe

A number of large investors have recently made changes to their positions in ME. FNY Investment Advisers LLC bought a new position in shares of 23andMe during the fourth quarter worth approximately $26,000. Leavell Investment Management Inc. bought a new position in 23andMe during the 4th quarter worth $32,000. MassMutual Private Wealth & Trust FSB bought a new position in 23andMe during the 4th quarter worth $40,000. AQR Capital Management LLC increased its stake in 23andMe by 145.8% during the 2nd quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock worth $174,000 after acquiring an additional 263,468 shares during the period. Finally, FMR LLC increased its stake in 23andMe by 24.0% during the 3rd quarter. FMR LLC now owns 993,848 shares of the company’s stock worth $345,000 after acquiring an additional 192,099 shares during the period. Institutional investors own 36.10% of the company’s stock.

About 23andMe

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.